Blog

In a groundbreaking development for vision care, India has approved PresVu, a new medication designed to significantly reduce the dependency on reading glasses for individuals suffering from presbyopia. This innovative eye drop, developed by ENTOD Pharmaceuticals, promises to transform the way millions manage age-related vision impairments.

Understanding Presbyopia

Presbyopia is a common condition that typically affects individuals aged 40 and above, characterised by the gradual loss of the eye’s ability to focus on nearby objects. As the natural lens of the eye becomes less flexible, tasks like reading or sewing can become increasingly challenging, leading many to rely on reading glasses. Globally, it is estimated that between 1.09 billion and 1.8 billion people are affected by this condition, highlighting the urgent need for effective treatments.

The Breakthrough of PresVu Eye Drops

The Drugs Controller General of India (DCGI) has granted final approval for PresVu, marking it as the first eye drop specifically developed to combat presbyopia in India. This approval follows extensive clinical trials and recommendations from the Central Drugs Standard Control Organisation (CDSCO).PresVu eye drops utilise dynamic buffer technology, allowing them to rapidly adapt to the pH of tears, ensuring consistent efficacy and safety for long-term use. The formulation not only aims to eliminate the need for reading glasses but also provides additional benefits, such as lubricating the eyes, which can enhance overall comfort.

How PresVu Works

The active ingredient in PresVu is pilocarpine, a well-known medication that works by constricting the pupils, thereby enhancing the depth of field and allowing for better near vision. Clinical studies have shown that a single application of PresVu can improve close-up vision within 15 minutes, with effects lasting up to six hours. For those who require extended relief, a second drop can be administered within a few hours to prolong the effect.

Clinical Trials and Efficacy

The development of PresVu involved rigorous clinical testing, including Phase 3 trials conducted in both India and the United States. These trials demonstrated that the eye drops are effective in providing swift relief from the symptoms of presbyopia, with participants reporting significant improvements in their ability to read and perform close-up tasks without the need for glasses.

Accessibility and Market Launch

ENTOD Pharmaceuticals plans to launch PresVu in the Indian market in the first week of October 2024, with a price point of approximately Rs 350 per bottle. The company is committed to making this innovative treatment accessible to all segments of society, aligning with the ‘Make in India’ initiative to produce affordable healthcare solutions domestically.

Expert Opinions

Industry experts have lauded the approval of PresVu as a significant advancement in ophthalmology. Dr. Dhananjay Bakhle, an ophthalmologist, noted, “The approval of PresVu is a promising development for patients with presbyopia, offering a non-invasive option to enhance near vision without the need for reading glasses.”Nikkhil K. Masurkar, CEO of ENTOD Pharmaceuticals, emphasised the transformative potential of PresVu, stating, “This product is more than just a medication; it represents a solution that can improve the lives of millions by granting them greater visual independence.”

The approval of PresVu eye drops is a significant milestone in the treatment of presbyopia, offering a promising alternative to traditional reading glasses. As the product prepares for its market launch, it holds the potential to enhance the quality of life for countless individuals struggling with age-related vision challenges.